Sharon Osbourne Before and After Ozempic: What She Confirmed and Why She Stopped

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited · Author: FormBlends Editorial

Key Takeaways

• Sharon Osbourne publicly confirmed Ozempic use in 2023 through interviews with British press and her appearance on Real Time with Bill Maher
• She has reported losing approximately 30 pounds, then discontinuing the medication because she felt she had lost too much weight
• Her case is one of the earliest high-profile celebrity confirmations and helped shift the cultural conversation toward more honest disclosure
• Her described experience (nausea, reduced appetite, excessive weight loss, feeling unwell) is consistent with clinical patient experiences when titration is fast or higher doses are used than the patient's body tolerates
• Her cautionary framing has been notable in the disclosure landscape: she has not disavowed the medication broadly but has warned about the risk of losing too much weight

Direct answer

Yes. Sharon Osbourne confirmed Ozempic use in interviews beginning in 2023. She reported losing roughly 30 pounds and stopping the medication because she felt the weight loss had become excessive. Her experience reflects a known clinical scenario: GLP-1 medications can produce substantial weight loss in patients with lower baseline BMIs, and patients sometimes discontinue not because the medication failed but because it worked beyond their goals. Her case is informative both for her honesty and for the cautionary framing she has used.

Table of contents

1. What Sharon Osbourne has confirmed and where
2. The timeline: from start to stop
3. The 30-pound loss in clinical context
4. Why she stopped: "too thin" as a discontinuation reason
5. Her side-effect profile
6. The "going too far" framing and its public health implications
7. How her case shifted celebrity disclosure norms
8. What her experience tells us about dosing in older women
9. The contrary view: is her cautionary framing overstated
10. The decision framework: what her case can teach a prospective patient
11. FAQ
12. Sources

What Sharon Osbourne has confirmed and where

Osbourne has discussed her Ozempic use publicly in multiple settings since 2023. The disclosure has been unusually candid for celebrity contexts where GLP-1 use is often denied or hedged.

Major disclosure events include:

• British press interviews in 2023, including coverage in The Mirror, in which she confirmed Ozempic use and described losing too much weight
• Her appearance on Real Time with Bill Maher in 2023, where she discussed the medication openly in front of a U.S. audience
• Additional commentary in interviews and on podcasts addressing her decision to stop and her current weight
• Subsequent interviews discussing regain and her broader perspective on the medication

The pattern of her disclosure has been distinctive. Rather than framing the confirmation as endorsement, she has framed it as warning. Her key public message has been that the medication is highly effective and that effectiveness itself can be a problem when it produces more weight loss than the patient wanted.

This framing has been notable because it acknowledges what many users experience but most public figures do not discuss: the medication can work too well. Patients sometimes stop not because they failed to lose weight but because they lost more than they intended.

The timeline: from start to stop

Period	Event
Early 2023	Osbourne reportedly begins Ozempic; specific start date not publicly confirmed
Spring 2023	Visible weight loss noted in public appearances
Mid-2023	Initial press coverage speculates about her appearance; she confirms Ozempic use in subsequent interviews
2023	Reports indicate she has stopped the medication; cites being too thin as the reason
2023-2024	Appearance on Real Time with Bill Maher discussing her experience
2024-2025	Continued interviews discussing partial weight regain and her current perspective

The total period of active use, based on her public discussion, appears to have been roughly 4-6 months. The pace of weight loss within that window suggests rapid response to the medication, which is consistent with reports from patients starting at lower baseline BMIs who often see faster percent-of-bodyweight loss than patients at higher BMIs.

Osbourne's reported height (approximately 5 feet 2 inches) and her pre-Ozempic weight (publicly speculated in the 150-160 pound range) would place her starting BMI in the 28-29 range, the overweight-to-mildly-obese boundary. At this profile, a 30-pound loss represents approximately 20% of her body weight, near the upper end of what semaglutide typically produces.

The 30-pound loss in clinical context

A 30-pound loss in 4-6 months for a patient at her starting profile sits at the upper edge of expected semaglutide outcomes. Published trial data provides the context:

Reference	Setting	Mean weight loss	Duration
STEP 1 (Wilding et al. 2021)	Semaglutide 2.4 mg in patients with obesity	14.9% of starting body weight	68 weeks
STEP 3 (Wadden et al. 2021)	Semaglutide 2.4 mg + intensive behavioral therapy	16.0%	68 weeks
STEP 4 (Rubino et al. 2021)	Semaglutide continuation after 20-week run-in	17.4% continued vs 5% loss with placebo	68 weeks total
SURMOUNT-1 (Jastreboff et al. 2022)	Tirzepatide 15 mg in patients with obesity	22.5%	72 weeks

Osbourne's reported 30-pound loss (approximately 20% of starting body weight) over 4-6 months exceeds the trial averages on both pace and magnitude. Several factors could explain this:

• Individual variation: trial averages obscure significant patient-to-patient variation; some patients lose substantially more than the mean
• Faster titration: if she titrated quickly, weight loss can compress into a shorter window
• Baseline diet: patients eating high-calorie diets at baseline often see more rapid initial loss as the medication reduces intake
• Concurrent behavioral changes: many patients also modify diet and activity, compounding the medication effect
• Lower baseline BMI: patients starting closer to normal weight sometimes show greater percent loss before plateau

Her outcome is not anomalous. It is at the upper edge of the distribution. The clinical signature (faster loss in a lower-BMI patient with reported reduced appetite and nausea) fits semaglutide therapy cleanly.

Why she stopped: "too thin" as a discontinuation reason

Osbourne's stated reason for stopping is clinically meaningful and often overlooked in public conversation about GLP-1 medications.

The conventional public narrative emphasizes patients who:

• Cannot lose weight despite trying
• Use medication, succeed, and continue
• Or use medication, fail, and stop

Osbourne represents a category often missing from public conversation: patients who use the medication, succeed beyond their goal, and stop because the medication is more effective than they wanted.

This pattern is meaningful for several reasons:

Reason 1: The medication's potency is variable.

Patient response to GLP-1 medications spans a wide range. Some patients lose 5-8% of body weight; others lose 20-25%. Predicting individual response is difficult before treatment. A patient with a 30-pound goal who responds strongly can exceed it before discontinuation can be coordinated.

Reason 2: Discontinuation has its own pattern.

Stopping GLP-1 therapy produces gradual return of appetite and slow weight regain, not immediate normalization. A patient who exceeds their goal will typically continue losing for several weeks after stopping before stabilizing.

Reason 3: Lower starting weights amplify the magnitude problem.

A patient starting at BMI 28 has less buffer between starting weight and an undesirable underweight state than a patient starting at BMI 40. The same percentage loss can produce different end states depending on baseline.

Reason 4: Goal setting is often inadequate.

Patients and clinicians frequently set treatment goals in pounds rather than in percentage of body weight or target BMI. Pound-based goals can be reached or exceeded faster than expected, leaving patients uncertain when to stop.

Osbourne's experience highlights that GLP-1 therapy requires active management throughout treatment, not just at initiation. Many patients benefit from regular check-ins and dose adjustments rather than fixed-dose protocols.

Her side-effect profile

Osbourne's publicly discussed side-effect experience is consistent with what is most commonly reported in clinical practice for semaglutide.

What she has described:

• Nausea during early treatment phases
• Significant appetite reduction
• Excessive weight loss as her primary concern
• Feeling weak or unwell during treatment
• Concerns about facial appearance and gaunt look

What she has not described publicly:

• Severe gastrointestinal events requiring hospitalization
• Pancreatitis (a rare but serious GLP-1 risk)
• Gallbladder issues (which can occur with rapid weight loss)
• Mood changes (which have been reported in some patients)

The profile she described is well-characterized in clinical trial data. The STEP 1 trial reported nausea in approximately 44% of semaglutide patients (vs. 18% with placebo), with most cases mild to moderate and resolving with continued treatment. Approximately 7% of patients discontinued due to gastrointestinal side effects.

Her decision to stop was based on weight rather than side effects. The side effects she described would not, on their own, typically warrant discontinuation. This makes her case distinct from the discontinuation pattern most commonly described in trial protocols.

The "going too far" framing and its public health implications

Osbourne's cautionary framing has had outsized public health impact relative to her individual experience.

The framing she has used in interviews:

• The medication works, often better than expected
• Patients should not assume they need to use it indefinitely
• The risk of losing too much weight is real and should be discussed before starting
• The aesthetic outcome ("gaunt," "too thin") can be undesirable
• Other patients should learn from her experience

This framing affects how prospective patients evaluate GLP-1 therapy. The pre-2023 conversation often emphasized whether the medication would work at all. The post-Osbourne conversation includes the question of how to manage success when it occurs.

Public health implications of her framing:

• Realistic expectations. Patients now hear that GLP-1 medications can be highly effective, not just modestly so. This is accurate.
• Pre-treatment goal setting. Her case underscores the value of defining target weight before treatment, not after.
• Active dose management. Lower or maintenance doses are options patients may consider once near-goal weight is achieved.
• Reduced moral framing of discontinuation. Stopping a medication is a clinical choice, not a failure.

The unintended consequence: her framing may dissuade some patients who would benefit from treatment if they associate it with "going too far." The clinical reality is that most patients lose appropriately when supervised, and most do not exceed their goals.

How her case shifted celebrity disclosure norms

Osbourne's confirmation was one of the earliest high-profile celebrity disclosures of GLP-1 use. The 2023 timing placed her ahead of the disclosure wave that intensified in 2024-2025.

Period	Confirmed celebrity users	Disclosure pattern
2021-2022	Elon Musk (Twitter, 2022)	Single voluntary disclosure; otherwise universal denial
2023	Sharon Osbourne, Chelsea Handler, Tracy Morgan, Amy Schumer	Comedy-adjacent and reality TV figures begin confirming
Q1 2024	Oprah Winfrey	First major mainstream figure confirms; disclosure becomes more common
Q2-Q4 2024	Whoopi Goldberg, Meghan Trainor, Kelly Clarkson	Television and music personalities confirm
2025	Serena Williams, Lainey Wilson, Christina Aguilera (partial)	Athletes and major artists; often with commercial partnerships

Osbourne occupied an unusual position in this evolution. As a long-established media personality with no current telehealth partnership at the time of her disclosure, her confirmation was not commercially structured. She was not paid to discuss the medication. Her disclosure pre-dated the marketing infrastructure that later disclosures (especially Williams's Ro partnership in 2025) were built around.

The implication: her account is unfiltered by partnership PR. Whatever she said reflects her experience as she chose to describe it, without coordination with a telehealth platform's marketing strategy. This makes her testimony more useful for clinical understanding than later partnership-structured disclosures.

What her experience tells us about dosing in older women

Osbourne was 70 at the time of her reported Ozempic use. Her case offers data points relevant to GLP-1 therapy in older women, though as a single case rather than systematic evidence.

Considerations specific to older women on GLP-1 therapy:

• Sarcopenia risk. Postmenopausal women have higher baseline risk of low lean mass. GLP-1 weight loss includes 25-40% lean mass per Wilding et al. 2021. Without adequate protein and resistance training, lean mass loss can be substantial.
• Bone health. Significant weight loss is associated with bone density reduction, particularly concerning in postmenopausal women already at risk of osteoporosis.
• Cardiovascular benefit. The SELECT trial demonstrated cardiovascular event reduction with semaglutide; older women with metabolic risk factors may particularly benefit.
• Drug interactions. Older women are more likely to use other medications (statins, blood pressure medications, hormone replacement) that need consideration in conjunction with GLP-1 therapy.
• Hydration sensitivity. Nausea-related dehydration affects older patients more severely; attention to fluid intake during titration is important.

Osbourne's reported experience (rapid loss, feeling unwell, decision to stop) is consistent with what specialists describe in older women who titrate quickly or who start at lower baseline BMIs. Her stopping decision, while not framed as a clinical contraindication, was probably appropriate given her described experience.

A more conservative protocol for older women might include slower titration, more frequent check-ins, attention to protein intake and resistance training, and earlier dose moderation as weight approaches goal. These adjustments do not require avoiding the medication; they support its appropriate use.

The contrary view: is her cautionary framing overstated

The strongest argument against weighting Osbourne's framing heavily: she is one patient, with one experience, and her cautionary frame may overgeneralize.

Argument 1: Selection effect on visible cases.

Celebrities who discuss their GLP-1 experience tend to be either extreme positive cases (impressive results, ongoing partnership) or extreme negative cases (uncomfortable side effects, dramatic loss). Patients with routine, satisfactory experiences are less likely to give interviews about it. Osbourne's case may overrepresent the high-magnitude tail of the response distribution.

Argument 2: Her starting BMI made the outcome predictable.

Patients starting at BMI 28-29 with strong response are at high risk of exceeding goal weight. A clinician would have been able to predict this risk before treatment. Her experience reflects the importance of pre-treatment counseling rather than a unique medication problem.

Argument 3: Most patients do not have this experience.

Trial data show mean weight loss of 14.9% with substantial variation. Most patients lose less than Osbourne reported. Her cautionary framing may discourage patients who would lose appropriately and not exceed their goal.

Argument 4: Aesthetic concerns are not universal.

Her concern about looking "too thin" reflects her aesthetic preferences and cultural context. Other patients may welcome more substantial weight loss. Generalizing her aesthetic concerns to all patients overstates the universality of the issue.

The counter:

Even granting these arguments, her case provides useful clinical information that the public conversation otherwise lacks. The reality that GLP-1 medications can produce weight loss exceeding patient goals is clinically real, even if it does not apply universally. Her cautionary framing adds nuance to a public conversation that otherwise tends toward two extremes: medication as miracle or medication as scandal.

The reasonable position: take her case as one informative data point among many. The medication can work strongly. Patient response varies. Pre-treatment goal setting matters. Ongoing dose management matters. These are the lessons her case illustrates.

The decision framework: what her case can teach a prospective patient

How should a person considering GLP-1 therapy read Osbourne's experience?

If you are considering GLP-1 therapy at a similar baseline BMI:

• Discuss expected response range with your prescriber before starting
• Set a target weight or BMI rather than a pound-loss goal
• Plan for regular check-ins to monitor pace of loss
• Be prepared to reduce dose or discontinue as you approach goal
• Maintain adequate protein intake (1.0-1.2 g/kg or higher) to preserve lean mass
• Include resistance training to support muscle retention

If you are at higher baseline BMI (BMI 35+):

• Her case is less directly applicable; patients at higher BMI have more buffer
• Substantial weight loss is generally medically beneficial in this range
• The "too thin" risk is much less relevant for patients with more weight to lose
• Her cautionary framing should not discourage appropriate treatment

If you are older (60+):

• Her case is one example of an older woman tolerating treatment, with strong response and chosen discontinuation
• Sarcopenia and bone health deserve particular attention
• Slower titration may produce a more comfortable experience
• Pre-treatment baseline labs (vitamin D, calcium, complete blood count) provide useful context

If you are concerned about the aesthetic outcome:

• Aesthetic concerns are individual; her experience may or may not align with yours
• Slower weight loss generally produces better-tolerated facial change
• Adequate protein and strength training help preserve facial muscle
• Dermatologic options (fillers, biostimulators) are available if needed without requiring medication discontinuation

FAQ

Did Sharon Osbourne take Ozempic? Yes. Sharon Osbourne publicly confirmed Ozempic use in 2023, including in interviews with British press and her appearance on Real Time with Bill Maher.

How much weight did Sharon Osbourne lose on Ozempic? Osbourne has reported losing approximately 30 pounds over the course of her Ozempic use. She stated the loss exceeded what she wanted.

Why did Sharon Osbourne stop Ozempic? Osbourne stated she stopped because she felt she had lost too much weight and felt unwell. The decision was hers, not a clinical contraindication.

What side effects did Sharon Osbourne have on Ozempic? She discussed nausea, reduced appetite, and excessive weight loss as her main experiences. She also referenced feeling generally unwell during treatment.

Did Sharon Osbourne gain the weight back after Ozempic? Osbourne has discussed regaining some of the lost weight after discontinuing, consistent with the published pattern of regain after GLP-1 discontinuation.

Does Sharon Osbourne regret taking Ozempic? Osbourne has expressed mixed views. She has described regret about the magnitude of weight loss while acknowledging she chose to use the medication.

What did Sharon Osbourne say on Bill Maher's show about Ozempic? She discussed her Ozempic use openly, including her weight loss magnitude and decision to stop. She framed the experience as a cautionary tale.

Is Ozempic dangerous for older women? GLP-1 medications have been studied in older adults. Specific concerns include sarcopenia risk, bone density implications, and hydration during gastrointestinal side effects. Use in older women is well established when medically indicated.

How fast did Sharon Osbourne lose weight on Ozempic? Based on her described timeline of 4-6 months of use and 30-pound loss, her pace was on the faster end of typical semaglutide response. Individual variation is significant.

Should I be afraid of losing too much weight on Ozempic? The risk exists, particularly for patients at lower baseline BMIs. Pre-treatment goal setting, regular monitoring, and willingness to adjust dose or discontinue can address the concern.

What is the difference between Ozempic and Wegovy? Both contain semaglutide as the active ingredient. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for chronic weight management at higher doses. The medications are produced by the same manufacturer (Novo Nordisk).

Can I use a lower dose to avoid losing too much weight? Yes. GLP-1 medications can be used at lower maintenance doses once weight goals are achieved. Some patients find lower doses adequate for maintaining loss; others may discontinue entirely. Dose adjustments should be made in consultation with the prescribing clinician.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023.
6. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
7. The Mirror. Interviews with Sharon Osbourne addressing Ozempic use. 2023.
8. HBO. Real Time with Bill Maher. Sharon Osbourne appearance. 2023-2024 season.
9. FDA Drug Approvals Database. Semaglutide (Ozempic, Wegovy) approval timelines and labeling.
10. Endocrine Society. Clinical Practice Guideline: Pharmacological Management of Obesity. 2023.
11. American Geriatrics Society. Considerations for Obesity Pharmacotherapy in Older Adults. 2024 position statement.
12. Garvey WT et al. American Association of Clinical Endocrinologists Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
13. Wilding JPH et al. Weight Regain and Cardiometabolic Effects after Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes, Obesity and Metabolism. 2022.

Footer disclaimers

FormBlends platform note. FormBlends is a digital health platform that introduces patients to independent licensed providers and U.S. state-licensed pharmacies. We do not manufacture medications, write prescriptions, or dispense pharmaceuticals. Clinical care decisions are made by the licensed provider in consultation with the patient.

Compounded medication note. Compounded semaglutide and compounded tirzepatide are formulations prepared by 503A compounding pharmacies in response to individual patient prescriptions. These preparations are not FDA-approved drug products, have not been reviewed under FDA approval pathways applicable to brand-name medications, and are not therapeutically equivalent to brand-name Ozempic, Wegovy, Mounjaro, or Zepbound.

Outcomes note. Individual responses to GLP-1 medications vary significantly. Published trial averages reflect group-level outcomes over defined study periods and do not predict outcomes for any specific patient. Sharon Osbourne's reported experience represents her individual case under specific conditions and is not representative of typical patient outcomes. Patients considering GLP-1 therapy should discuss expected outcomes, risks, and management strategies with a licensed clinician.

Trademark note. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Real Time with Bill Maher is an HBO production. The Mirror is a publication of Reach plc. FormBlends has no commercial, sponsorship, or other affiliation with Sharon Osbourne, the Osbourne family, HBO, Reach plc, Novo Nordisk, Eli Lilly, or any other party referenced in this article.